Behrens Baumann dust syndrome

Summary

Behrens Baumann dust syndrome (MONDO:0022557) is a disease. A subtype of cerebellar disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Behrens Baumann dust syndrome
Mondo ID	MONDO:0022557
MeSH	C537670
UMLS	C2931582
MedGen	444092
GARD	0004021
Is cancer (heuristic)	no

Also known as: Behrens-Baumann-Vogel syndrome · microphthalmia-optic nerve dysplasia · oculo-cerebral dysplasia · unilateral aplasia of the optic nerve with cryptophthalmus and contralateral microphthalmus

Disease family

This is a subtype of cerebellar disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebellar disorder › Behrens Baumann dust syndrome

Related subtypes (4): cerebellar neoplasm, Miller Fisher syndrome, Dandy-Walker syndrome, cerebellar degeneration

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.